---

A single, unopened Vyvanse prescription bottle with a bright orange "RECALL" tag attached, sharp focus, clean background.

---

Vyvanse Recall: What You Need to Know

Recent Recalls and Safety Alerts

Generic Lisdexamfetamine Dimesylate Recall (United States)

On October 28, 2025, Sun Pharmaceutical Industries, Inc. initiated a nationwide recall of several lots of generic lisdexamfetamine dimesylate capsules, the generic form of Vyvanse. This recall affects multiple dosage strengths:

• 10 mg capsules


• 20 mg capsules


• 30 mg capsules


• 40 mg capsules


• 50 mg capsules


• 60 mg capsules


• 70 mg capsules

Reason for Recall: The medication failed dissolution tests, which are critical for ensuring proper drug absorption and effectiveness. These tests verify that the medication will dissolve correctly in the body to provide the intended therapeutic effect.

Safety Information: Health officials have confirmed that taking the recalled medication does not pose safety or health risks. The primary concern is reduced efficacy rather than safety issues.

Vyvanse Packaging Alert (Australia)

In April 2025, Takeda Pharmaceuticals Australia Pty Ltd issued a product alert for Vyvanse capsules in multiple strengths (20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg) due to packaging errors.

Packaging Issues: The alert was triggered by minor typographical errors on the packaging, including:


• "Each capsules contain..." instead of "Each capsule contains..."


• "Pharmaceutivals" instead of "Pharmaceuticals"

Impact Assessment: The Therapeutic Goods Administration (TGA) confirmed that these typographical errors did not affect the quality, safety, or efficacy of the Vyvanse capsules themselves.

What Patients Should Do

For the U.S. Generic Recall



• Contact your healthcare provider or pharmacy to determine if your medication is affected


• Request replacement medication or refunds for recalled products


• Do not stop taking your medication without consulting your healthcare provider first

For the Australian Packaging Alert



• Continue taking your medication as prescribed


• The packaging errors do not affect the medication's safety or effectiveness


• Contact your pharmacist if you have concerns about your specific packaging

Important Considerations

• These recalls affect specific batches and regions only


• The brand-name Vyvanse product is not subject to the U.S. dissolution recall


• Patients should always verify their medication lot numbers with their pharmacists


• Never discontinue ADHD medication without medical supervision

Monitoring and Reporting

Patients experiencing any issues with their medication should:


• Report concerns to their healthcare provider


• Contact the manufacturer directly


• Report adverse events to relevant health authorities (FDA in the U.S., TGA in Australia)

Always consult with healthcare professionals for personalized medical advice regarding your specific situation and medication needs.

---

The prompt for this was: vyvanse recall

---

Visit BotAdmins for done for you business solutions.